Updated July 2026. Field milestone: UB-312 (Vaxxinity, C-terminal α-synuclein peptide + T-helper epitope) became the first active immunotherapy to show reduction of pathological α-synuclein in cerebrospinal fluid of Parkinson's patients. Phase 1 Part B results (20 early-PD patients, published in Nature Medicine, exploratory biomarker work funded by The Michael J. Fox Foundation in collaboration with Mayo Clinic and UTHealth Houston) showed 12 of 13 vaccinated patients developed α-synuclein antibodies, four of six patients at the 300/100/100 μg dose had CSF antibodies, and vaccinated participants with detectable CSF antibodies showed decreased seeded aggregation and MDS-UPDRS Part II motor improvement. Vaxxinity is now planning a Phase 2 trial and has an ongoing 4+4 patient MSA/PD Phase 1b at NYU (three prime doses + five boosters over 2 years). ACI-7104.056 (AC Immune, an optimized formulation of the original AFFiRiS PD01A) began a Phase 2 trial in July 2023 and is ongoing. Passive immunotherapies (prasinezumab from Roche/Prothena; cinpanemab from Biogen) continue as complementary approaches. Together these represent the first credible chance at disease modification in Parkinson's since levodopa's introduction.
Comprehensive tracking of Parkinson's disease (PD) therapeutic vaccine development targeting alpha-synuclein protein aggregation, neuroinflammation, and dopaminergic neuron degeneration. Parkinson's affects 1 million US adults, 10 million globally - second most common neurodegenerative disease after Alzheimer's. Progressive movement disorder causing tremor, rigidity, bradykinesia, postural instability. Therapeutic vaccines aim to induce antibodies clearing toxic alpha-synuclein aggregates (Lewy bodies), slow neurodegeneration, preserve dopamine neurons. Active immunization (PD01A, PD03A, AFFITOPE) and passive immunotherapy (prasinezumab, cinpanemab) in Phase 1-2 trials. Novel approach targeting disease pathology vs. symptomatic dopamine replacement. Complementary to current medications (levodopa, dopamine agonists) and exercise interventions.
Parkinson's affects 1 million Americans, 10 million globally. Incidence rising: 90,000 new US diagnoses/year. Most common movement disorder and second most common neurodegeneration (after Alzheimer's). Age-related: <1% under 60, 1% age 60+, 4% over 80. Men affected 1.5x more than women. Progressive disability: tremor, rigidity, bradykinesia (slowness), postural instability, falls, freezing of gait. Non-motor symptoms: depression (50%), cognitive impairment/dementia (30-80%), sleep disorders, constipation, loss of smell. Average survival 15-20 years post-diagnosis but quality of life severely impaired. No cure available - current treatments (levodopa, dopamine agonists, MAO-B inhibitors, deep brain stimulation) only manage symptoms temporarily, lose efficacy over time. Motor fluctuations and dyskinesias develop. Therapeutic vaccines offer hope for disease modification - slowing/stopping neurodegeneration by targeting underlying alpha-synuclein pathology.
📊 View all Parkinson's vaccine trials on ClinicalTrials.gov →
🌍 Parkinson's Foundation →
🌍 Michael J. Fox Foundation →
🌍 NINDS Parkinson's Information →
📰 Latest Parkinson's Vaccine News (Google) →